Novel AMPA receptor antagonist

Potent and selective mGLu1 antagonist

Selective growth inhibitor of endothelial cells

Novel non-analogous leukotriene agonist

Novel Inducer of Apoptosis in Human Colorectal Cells via Mitochondrial Apoptosis Pathway, Inhibiting Tumor Growth

Novel, Orally Active Bioavailable Inhibitor of VEGFR2 Signaling with Potent Antiangiogenic Activity and Antitumor Efficacy

Novel salt inducible kinase (SIK) inhibitor, increasing bone formation and bone mass

Novel dual action combretastatin A-4 (CA-4) prodrug, releasing CA-4 through a disulfide bond cleavage mechanism and containing a near-infrared (NIR) fluorophore

Novel glucokinase activator, significantlt decreasing in blood glucose levels with no adverse effects on serum lipids or body weight

Novel GPR119 Agonist, improving glucose tolerance and augmenting the glucose lowering effect as well as the plasma level of active GLP-1 in normal mice in combination treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor

Novel Inhibitor of Antiapoptotic Bcl-2 Family Proteins

Tamoxifen-analog that Suppresses Glial L-Glutamate Transport Activity without Interaction with Estrogen_receptor>Estrogen Receptors

Selective Rho-associated kinase (ROCK) inhibitor

Novel, selective, soluble non-​peptidic NPY Y2 receptor antagonist with enhanced CNS exposure

Novel non-peptidic highly potent, soluble and selective NPY Y2 antagonist

Novel TRIM24/BRPF1 dual inhibitor with IC 50 values of 0.98 and 1.16 μM, respectively

Novel activator of p21 promoter in a p53-independent manner

Carbonic anhydrase inhibitor; Fungal metabolite

Novel selective β-catenin degrader

Potent modulator of P-glycoprotein-mediated multidrug resistance (MDR), inhibiting the binding of cytotoxics to P-glycoprotein

Novel Akt1/2 inhibitor

Novel Potent Pan-Filovirus Inhibitor, showing potent inhibition against infectious EBOV Zaire (0.09 μM) and MARV (0.64 μM)

Novel dual inhibitor of AF9 and ENL YEATS domains

Novel non-coding RNA prototype Xist ligand, specifically binding the RepA motif of Xist, reducing the conformational space of RepA, displacing cognate interacting protein factors (PRC2 and SPEN), suppressing histone H3K27 trimethylation, and blocking init

Novel INK4C inhibitor, specifically blocking the bioactivity of p18 protein and promoting human and murine hematopoietic stem cell ex vivo expansion

Potent and Selective Stearoyl-CoA Desaturase-1 Inhibitor

Novel PKM2 activator

Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $26.55 Total: $2,655.00 50 $30.68 Total: $1,534.00 25 $35.99 Total: $899.75 10 $42.48 Total: $424.80 5 $50.15 Total: $250.75

Novel antibiotic, showing 3- to 10-fold greater cytotoxicity than Xantholipin against a select panel of human cancer cell lines, demonstrating powerful antimicrobial activity against both Gram-positive bacteria and fungi

Antibiotic, exhibiting strong antibacterial activities and showing potent cytotoxicity, inhibiting HSP47 gene expression produced by Streptomyces sp